All In Biotech

Free tool

FAERS Monitor: Tryngolza (Autoinjector)

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 218614 or its brand name (Tryngolza (Autoinjector), Olezarsen Sodium). Reports on generic versions are filed under their own applications.

Reports

947

Serious

201

21% of reports

Hospitalization

131

Death reported

4

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • injection site pain84
  • blood triglycerides increased82
  • injection site erythema77
  • product dose omission issue63
  • off label use57
  • arthralgia40
  • nausea36
  • pancreatitis35
  • pancreatitis acute34
  • injection site swelling33
  • fatigue30
  • injection site rash30
  • blood glucose increased29
  • injection site bruising29
  • abdominal pain27

Reports by year received

View as table
YearReports
2025152
2026795

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,212 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
blood triglycerides increasedSignal82103.684.28,196
pancreatitis acuteSignal3433.624.21,044
injection site rashSignal3021.715.3573
pancreatitisSignal3514.710.6435
injection site erythemaSignal7713.811.1906
injection site swellingSignal339.66.8246
injection site bruisingSignal298.15.6173
injection site painSignal846.15.0357
product dose omission issueSignal634.83.7186
blood glucose increasedSignal293.42.448
abdominal painSignal272.61.825
arthralgiaSignal402.11.624
off label use571.41.18
nausea361.00.70
fatigue300.90.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.